130 related articles for article (PubMed ID: 37962220)
21. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
22. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
[TBL] [Abstract][Full Text] [Related]
23. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
24. Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.
Meyer N; Pérol D; Duval-Modeste AB; El Adaoui L; Lelarge Y; Niarra R; Mateus C
Melanoma Res; 2022 Aug; 32(4):269-277. PubMed ID: 35635532
[TBL] [Abstract][Full Text] [Related]
25. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF
Lewis K; Hauschild A; Larkin J; Ribas A; Flaherty KT; McArthur GA; Dréno B; McKenna E; Zhu Q; Mun Y; Ascierto PA
Eur J Cancer; 2019 Jul; 116():45-55. PubMed ID: 31173962
[TBL] [Abstract][Full Text] [Related]
26. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With
Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; di Pietro A; Cantey-Kiser J; Edwards M; Ascierto PA
J Clin Oncol; 2022 Dec; 40(36):4178-4188. PubMed ID: 35862871
[TBL] [Abstract][Full Text] [Related]
27. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
Keating GM
Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
[TBL] [Abstract][Full Text] [Related]
28. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
Livingstone E; Gogas H; Kandolf-Sekulovic L; Meier F; Eigentler TK; Ziemer M; Terheyden PAM; Gesierich AH; Herbst RA; Kähler KC; Ziogas DC; Mijuskovic Z; Garzarolli M; Garbe C; Roesch A; Ugurel S; Gutzmer R; Grob JJ; Kiecker F; Utikal J; Windemuth-Kieselbach C; Eckhardt S; Zimmer L; Schadendorf D
Eur J Cancer; 2023 Sep; 190():112941. PubMed ID: 37482012
[TBL] [Abstract][Full Text] [Related]
29. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
30. [Treatment combinations in BRAF-mutant metastatic melanoma.].
Depenni R
Recenti Prog Med; 2021 Apr; 112(4):40e-43e. PubMed ID: 33877098
[TBL] [Abstract][Full Text] [Related]
31. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
33. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
[TBL] [Abstract][Full Text] [Related]
34. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
35. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
[TBL] [Abstract][Full Text] [Related]
36. Safety of vemurafenib in patients with BRAF
Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
[TBL] [Abstract][Full Text] [Related]
37. Vemurafenib in Chinese patients with BRAF
Si L; Zhang X; Xu Z; Jiang Q; Bu L; Wang X; Mao L; Zhang W; Richie N; Guo J
BMC Cancer; 2018 May; 18(1):520. PubMed ID: 29724167
[TBL] [Abstract][Full Text] [Related]
38. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
Simeone E; Scognamiglio G; Capone M; Giannarelli D; Grimaldi AM; Mallardo D; Madonna G; Curvietto M; Esposito A; Sandomenico F; Sabbatino F; Bayless NL; Warren S; Ong S; Botti G; Flaherty KT; Ferrone S; Ascierto PA
J Transl Med; 2021 Jan; 19(1):17. PubMed ID: 33407577
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
Li SN; Wan X; Peng LB; Li YM; Li JH
BMC Health Serv Res; 2023 Jan; 23(1):49. PubMed ID: 36653848
[TBL] [Abstract][Full Text] [Related]
40. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]